Vor Bio's Partner RemeGen Achieves Primary Endpoint in Telitacicept Trial for Sjögren's Disease Treatment in China.

Vor Bio's partner RemeGen has successfully completed a late-stage trial in China for telitacicept, a treatment for Sjögren's disease. The trial met the main goal, and Vor Bio's shares rose in response.

Vor Bio (NASDAQ: VOR) and its partner RemeGen (OTCPK: REGMF) have announced significant progress in the development of telitacicept, a treatment for Sjögren's disease. The companies reported that a late-stage trial conducted in China successfully met its primary endpoint, leading to a notable increase in Vor Bio's stock price.

The trial, which focused on primary Sjögren's syndrome (pSS), demonstrated that telitacicept effectively improved patients' symptoms and exhibited a favorable safety profile [1]. RemeGen, the developer of telitacicept, plans to file for regulatory approval in China and will present detailed results at upcoming international medical conferences [1].

Sjögren's syndrome is a chronic inflammatory autoimmune disease that primarily affects the eyes and mouth, causing dryness and other debilitating symptoms. The condition affects millions of people worldwide, with estimates suggesting around 4 million to 10 million people in China alone [1]. Telitacicept targets two cell-signaling molecules, B lymphocyte stimulator (BlyS) and A proliferation-inducing ligand (APRIL), which are crucial for B-lymphocyte development and the production of autoantibodies [2].

In June, Vor Bio entered into a licensing agreement with RemeGen, acquiring ex-China rights to telitacicept for a total upfront payment of $125 million in cash and stock [2]. This deal represents a strategic pivot for Vor Bio, which had previously focused on blood cancer therapies. The company is now aiming to advance telitacicept through a global Phase 3 trial in myasthenia gravis and potentially expand its clinical development to include Sjögren's disease [2].

The success of the late-stage trial in China is a significant milestone for both Vor Bio and RemeGen. The trial's positive results, along with the drug's existing approvals for systemic lupus erythematosus (SLE), rheumatoid arthritis, and generalized myasthenia gravis (gMG) in China, position telitacicept as a promising treatment for autoimmune diseases [1]. The stock market's positive reaction to the trial results underscores investor confidence in the drug's potential.

Looking ahead, Vor Bio and RemeGen will continue to collaborate to advance telitacicept through its global clinical development program. The companies' strategic partnership and the drug's potential to treat a wide range of autoimmune diseases make telitacicept an attractive candidate for further investment and development [2].

References:
[1] https://www.fiercepharma.com/pharma/remegens-ph-3-sjogrens-win-china-bodes-well-recent-vor-bio-licensing-pact
[2] https://www.biopharmadive.com/news/remegen-vor-telitacicept-sjorgens-phase-3-study/757532/